2023年4月5日

分享這篇文章提供的新聞分享本文都柏林,2023年4月4日——“眼部植入2023年全球市場報告”報告已添加到ResearchAndMarkets.com的祭。全球眼植入市場從120.3億年的2022美元增加到129.8億年的2023美元,複合年增長率(CAGR)的8.0%。眼植入市場預計將增長到176.6億年的2027美元的CAGR為8.0%。使用眼部植入提高眼睛視力的人。這些植入物有助於提高解決眼前的人已經失去了一隻眼睛受傷或疾病,通常稱為玻璃假眼,硬塑料丙烯酸組成。義眼有殼形式,組成的一個清晰的、人工晶狀體植入,用於替換一個多雲的自然鏡頭在白內障手術。北美最大的地區是眼部植入市場在2022年。亞太地區天氣預報預計將增長最快的地區。眼植入物的區域覆蓋亞太市場報告,西歐、東歐、北美、南美、中東和非洲。眼科疾病的日益普及世界各地將是增長的主要驅動力的眼部植入市場。 The foremost common eye disorders within the U.S. Isis refractive errors. For instance, in 2022 in line with American Academy Of Ophthalmology (AAO) offer statistics on the prevalence of visual defect because of eye disorders by ethnicity yet because the breakdown of individuals who are legally blind thanks to eye diseases or eye disorders by grouping. Within the United States alone, about 12 million people aged 40 and above suffer from vision impairment, with about a million full of blindness globally, the similar reports about 2.2 billion individuals have eye and visual disorders, according to the world health organization. Hence, the rising prevention of eye disorders, is anticipated more demand for ocular implants increasing prevalence of eye disorders like cataract and glaucoma is to fuel the demand for ocular implants. Technological advancements and innovations has been a key trend gaining popularity in the ocular implants market. Technological advancements are the discovery of knowledge that helps in developing products using advanced technology. Major companies operating in the ocular implants market are focused on developing new technological solutions to meet customer demand and make ocular implants more advanced. For instance, in July 2021, ZEISS, a Germany-based manufacturer of optical systems and optoelectronics, introduced ZEISS Medical Ecosystem. The ZEISS Medical Ecosystem is an entirely integrated setting that uses various tools for data management, apps, and services to enhance patient outcomes continuously. This ecosystem's unique combination of unmatched ocular knowledge and cutting-edge digital technology makes it possible to make decisions based on the best available data, ensuring the most effective treatment delivery on a single, secure platform. In August 2021, Alcon, a Switzerland-based medical company offering dedicated eye care, announced acquisition of Ivantis, $475 million in cash up front. The aim of this acquisition demonstrates Alcon's commitment to the surgical glaucoma market, bolstering the company's industry-leading portfolio in cataract, refractive, retina, and glaucoma. Ivantis is a US-based company the developing and manufacturing the Hydrus Microstent, a novel minimally invasive glaucoma surgery (MIGS) device the designed to lower intraocular pressure in open-angle glaucoma patients during cataract surgery. Reasons to Purchase Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies. Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates. Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market. Measure the impact of high global inflation on market growth. Create regional and country strategies on the basis of local data and analysis. Identify growth segments for investment. Outperform competitors using forecast data and the drivers and trends shaping the market. Understand customers based on the latest market shares. Benchmark performance against key competitors. Suitable for supporting your internal and external presentations with reliable high quality data and analysis Scope